ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0909

Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Abstract Number: 0910

Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2
Abstract Number: 0911

Impact of Filgotinib on Structural Lesions in the Sacroiliac Joints at 12 Weeks in Patients with Active Ankylosing Spondylitis: Correlation with Clinical Endpoints
Abstract Number: 0912

Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension
Abstract Number: 0913

Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study
Abstract Number: 0914

Serious Infections in People with Systemic Sclerosis: A National U.S. Study
Abstract Number: 0915

Clinical Bedside Tools to Assess Systemic Sclerosis Vasculopathy: Can Digital Thermal Monitoring and Sublingual Microscopy Identify Patients with Current or past Digital Ulcers?
Abstract Number: 0916

Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Abstract Number: 0917

Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Abstract Number: 0918

Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Abstract Number: 0919

Determinants of Health-related Quality of Life in Systemic Sclerosis
Abstract Number: 0920

Machine Learning Assisted Prediction of Progression in Systemic Sclerosis Patients: An Approach to Concise, Tailored Model Construction Using Outpatient Clinical Data
Abstract Number: 0921

The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort
Abstract Number: 0922

Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
Abstract Number: 0923

Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].